Abstract
Hypoxia-inducible factors (HIFs) are the main regulatory factors implicated in the adaptation of cancer cells to hypoxic stress, which has provoked much interest as an attractive target for the design of promising chemotherapeutic agents. Since indirect HIF inhibitors (HIFIs) lead to the occurrence of various side effects, the need of the hour is to develop direct HIFIs, physically interacting with important functional domains within the HIF protein structure. Accordingly, in the present study, it was attempted to develop an exhaustive structure-based virtual screening (VS) process coupled with molecular docking, molecular dynamic (MD) simulation, and MM-GBSA calculations for the identification of novel direct inhibitors against the HIF-2α subunit. For this purpose, a focused library of over 200,000 compounds from the NCI database was used for VS against the PAS-B domain of the target protein, HIF-2α. This domain was suggested to be a possible ligand-binding site, which is characterized by a large internal hydrophobic cavity, unique to the HIF-2α subunit. The top-ranked compounds, NSC106416, NSC217021, NSC217026, NSC215639, and NSC277811 with the best docking scores were taken up for the subsequent in silico ADME properties and PAINS filtration. The selected drug-like hits were employed for carrying out MD simulation which was followed by MM-GBSA calculations to retrieve the candidates showing the highest in silico binding affinity towards the PAS-B domain of HIF-2α. The analysis of results indicated that all molecules, except the NSC277811, fulfilled necessary drug-likeness properties. Four selected drug-like candidates, NSC106416, NSC217021, NSC217026, and NSC215639 were found to expose the stability profiles within the cavity located inside the PAS-B domain of HIF-2α over simulation time. Finally, the results of the MM-GBSA rescoring method were indicative of the highest binding affinity of NSC217026 for the binding site of the HIF-2α PAS-B domain among selected final hits. Consequently, the hit NSC217026 could serve as a promising scaffold for further optimization toward the design of direct HIF-2α inhibitors for cancer therapy.
Similar content being viewed by others
Data availability
Relevant data associated with this study are contained within the article or in supplementary material.
Code availability
Not applicable.
References
Vaupel P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26(2):225–239. https://doi.org/10.1007/s10555-007-9055-1
Graham K, Unger E (2018) Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomed 13:6049. https://doi.org/10.2147/ijn.s140462
Liao D, Johnson RS (2007) Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26(2):281–290. https://doi.org/10.1007/s10555-007-9066-y
Lu X, Kang Y (2010) Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 16(24):5928–5935. https://doi.org/10.1158/1078-0432.ccr-10-1360
Akanji MA, Rotimi D, Adeyemi OS (2019) Hypoxia-inducible factors as an alternative source of treatment strategy for cancer. Oxid Med Cell Longev 2019:8547846. https://doi.org/10.1155/2019/8547846
Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, Meng L, Xin Y, Jiang X (2021) Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res 40(1):24. https://doi.org/10.1186/s13046-020-01820-7
Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, Shu Y (2019) Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer 18(1):157. https://doi.org/10.1186/s12943-019-1089-9
Ke Q, Costa M (2006) Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 70(5):1469–1480. https://doi.org/10.1124/mol.106.027029
Greer SN, Metcalf JL, Wang Y, Ohh M (2012) The updated biology of hypoxia-inducible factor. EMBO J 31(11):2448–2460. https://doi.org/10.1038/emboj.2012.125
Webb JD, Coleman ML, Pugh CW (2009) Hypoxia, hypoxia-inducible factors (HIF), HIF hydroxylases and oxygen sensing. Cell Mol Life Sci 66(22):3539–3554. https://doi.org/10.1007/s00018-009-0147-7
Déry M-AC, Michaud MD, Richard DE (2005) Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int J Biochem Cell Biol 37(3):535–40. https://doi.org/10.1016/j.biocel.2004.08.012
Semenza GL (2001) Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. Trends Mol Med 7(8):345–350. https://doi.org/10.1016/s1471-4914(01)02090-1
Patel SA, Simon MC (2008) Biology of hypoxia-inducible factor-2 α in development and disease. Cell Death Differ 15(4):628–634. https://doi.org/10.1038/cdd.2008.17
Duan C (2016) Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am J Physiol Cell Physiol 310(4):C260–C269. https://doi.org/10.1152/ajpcell.00315.2015
Choudhry H, Harris AL (2018) Advances in hypoxia-inducible factor biology. Cell Metab 27(2):281–298. https://doi.org/10.1016/j.cmet.2017.10.005
Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B (2013) Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem 5(5):553–572. https://doi.org/10.4155/fmc.13.17
Tang W, Zhao G (2020) Small molecules targeting HIF-1α pathway for cancer therapy in recent years. Bioorg Med Chem 28(2):115235. https://doi.org/10.1016/j.bmc.2019.115235
Fallah J, Rini BI (2019) HIF inhibitors: status of current clinical development. Curr Oncol Rep 21(1):6. https://doi.org/10.1007/s11912-019-0752-z
Hu C-J, Sataur A, Wang L, Chen H, Simon MC (2007) The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol Biol Cell 18(11):4528–4542. https://doi.org/10.1091/mbc.e06-05-0419
Brahimi-Horn MC, Pouysségur J (2009) HIF at a glance. J Cell Sci 122(8):1055–1057. https://doi.org/10.1242/jcs.035022
Li Z, You Q, Zhang X (2019) Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem 62(12):5725–5749. https://doi.org/10.1021/acs.jmedchem.8b01596
Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, Garcia JA, Naidoo J, Longgood J, Frantz DE, Tambar UK, Gardner KH, Bruick RK (2013) Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 9(4):271–276. https://doi.org/10.1038/nchembio.1185
Key J, Scheuermann TH, Anderson PC, Daggett V, Gardner KH (2009) Principles of ligand binding within a completely buried cavity in HIF2alpha PAS-B. J Am Chem Soc 131(48):17647–17654. https://doi.org/10.1021/ja9073062
Scheuermann TH, Stroud D, Sleet CE, Bayeh L, Shokri C, Wang H, Caldwell CG, Longgood J, MacMillan JB, Bruick RK, Gardner KH, Tambar UK (2015) Isoform-selective and stereoselective inhibition of hypoxia inducible factor-2. J Med Chem 58(15):5930–5941. https://doi.org/10.1021/acs.jmedchem.5b00529
Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, Gardner KH (2009) Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci USA 106:450–455. https://doi.org/10.1073/pnas.0808092106
Erbel PJ, Card PB, Karakuzu O, Bruick RK, Gardner KH (2003) Structural basis for PAS domain heterodimerization in the basichelix–loop–helix-PAS transcription factor hypoxia-inducible factor. Proc Natl Acad Sci USA 100:15504–15509. https://doi.org/10.1073/pnas.2533374100
Wehn PM, Rizzi JP, Dixon DD, Grina JA, Schlachter ST, Wang B, Xu R, Yang H, Du X, Han G, Wang K (2018) Design and activity of specific hypoxia-inducible factor-2α (HIF-2α) inhibitors for the treatment of clear cell renal cell carcinoma: discovery of clinical candidate (S)-3-((2,2-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J Med Chem 61(21):9691–9721. https://doi.org/10.1021/acs.jmedchem.8b01196
Cho H, Du X, Rizzi JP, Liberzon E, Chakraborty AA, Gao W, Carvo I, Signoretti S, Bruick RK, Josey JA, Wallace EM, Kaelin WG (2016) On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. Nature 539:107–111. https://doi.org/10.1038/nature19795
Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, Cheng T, Czerwinski RM, Dixon DD, Goggin BS, Grina JA, Halfmann MM, Maddie MA, Olive SR, Schlachter ST, Tan H, Wang B, Wang K, Xie S, Xu R, Yang H, Josey JA (2016) A smallmolecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma. Cancer Res 76(18):5491–5500. https://doi.org/10.1158/0008-5472.can-16-0473
Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, Homayoun F, Ma Y, Patel N, Yell P, Hao G, Yousuf Q, Joyce A, Pedrosa I, Geiger H, Zhang H, Chang J, Gardner KH, Bruick RK, Reeves C, Hwang TH, Courtney K, Frenkel E, Sun X, Zojwalla N, Wong T, Rizzi JP, Wallace EM, Josey JA, Xie Y, Xie X-J, Kapur P, McKay RM, Brugarolas J (2016) Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539:112–117. https://doi.org/10.1038/nature19796
Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, Zojwalla NJ, Lowe AM, Wang K, Wallace EM, Josey JA, Choueiri TK (2018) Phase I dose escalation trial of PT2385, a first-in-class hypoxia inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol 36:867–874. https://doi.org/10.1200/jco.2017.74.2627
Xu R, Wang K, Rizzi JP, Huang H, Grina JA, Schlachter ST, Wang B, When PM, Yang H, Dixon DD, Czerwinski RM (2019) 3-[(1S,2S,3R)-2,3-difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2α (HIF-2α) inhibitor for the treatment of clear cell renal cell carcinoma. J Med Chem 62:6876–6893
Schrödinger LLC (2015) Version 3.3, LigPrep. Schrödinger, LLC, New York
Sirous H, Chemi G, Gemma S, Butini S, Debyser Z, Christ F, Saghaie L, Brogi S, Fassihi A, Campiani G, Brindisi M (2019) Identification of novel 3-hydroxypyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach. Front Chem 7:574. https://doi.org/10.3389/fchem.2019.00574
Sirous H, Campiani G, Calderone V, Brogi S (2021) Discovery of novel hit compounds as potential HDAC1 inhibitors: the case of ligand-and structure-based virtual screening. Comput Biol Med 137:104808. https://doi.org/10.1016/j.compbiomed.2021.104808
Epik (2015) Epik version 3.4. Schrödinger, LLC, New York
Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M (2007) Epik: a software program for pK a prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des 21:681–691. https://doi.org/10.1007/s10822-007-9133-z
Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225–11236. https://doi.org/10.1021/ja9621760.10.1021/acs.jctc.9b00054
Bernstein FC, Koetzle TF, Williams GJ, Meyer JF, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M (1977) The Protein Data Bank: a computer-based archival file for macromolecular structures. J Mol Biol. https://doi.org/10.1016/S0022-2836(77)80200-3
Protein preparation wizard 2015, -1; Epik version 2.4, Schrödinger, LLC, New York, 2015; Impact version 5.9, Schrödinger, LLC, New York, 2015; Prime version 3.2, Schrödinger, LLC, New York, 2015
Sastry GM, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234. https://doi.org/10.1007/s10822-013-9644-8
Thomsen R, Christensen MH (2006) MolDock: a new technique for high-accuracy molecular docking. J Med Chem 49(11):3315–3321. https://doi.org/10.1021/jm051197e
Desmond Molecular Dynamics System, version 5.6, D. E. Shaw Research, New York, 2018. Maestro-Desmond Interoperability Tools, Schrödinger, New York, 2018
Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935. https://doi.org/10.1063/1.445869
Jorgensen WL, Maxwell DS, Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225–11236. https://doi.org/10.1021/ja9621760
Brogi S, Sirous H, Calderone V, Chemi G (2020) Amyloid β fibril disruption by oleuropein aglycone: long-time molecular dynamics simulation to gain insight into the mechanism of action of this polyphenol from extra virgin olive oil. Food Funct 11(9):8122–8132. https://doi.org/10.1039/D0FO01511C
Humphreys DD, Friesner RA, Berne BJ (1994) A multiple-time-step molecular dynamics algorithm for macromolecules. J Phys Chem 98:6885–6892. https://doi.org/10.1021/j100078a035
Hoover WG (1985) Canonical dynamics: equilibrium phase-space distributions. Phys Rev A 31:1695. https://doi.org/10.1103/PhysRevA.31.1695
Martyna GJ, Tobias DJ, Klein ML (1994) Constant pressure molecular dynamics algorithms. J Chem Phys 101:4177–4189. https://doi.org/10.1063/1.467468
Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LGA (1995) Smooth particle mesh Ewald method. J Chem Phys 103:8577–8593. https://doi.org/10.1063/1.470117
Huang N, Kalyanaraman C, Irwin JJ, Jacobson MP (2006) Physics-based scoring of protein–ligand complexes: enrichment of known inhibitors in large-scale virtual screening. J Chem Inf Model 46:243–253. https://doi.org/10.1021/ci0502855
Kuhn B, Kollman PA (2000) Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J Med Chem 43:3786–3791. https://doi.org/10.1021/jm000241h
Sun H, Li Y, Tian S, Xu L, Hou T (2014) Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. Phys Chem Chem Phys 16:16719–16729. https://doi.org/10.1039/c4cp01388c
Sun H, Li Y, Shen M, Tian S, Xu L, Pan P, Guan Y, Hou T (2014) Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring. Phys Chem Chem Phys 16:22035–22045. https://doi.org/10.1039/c4cp03179b
Schrödinger. Command-line only scripts. https://www.schrodinger.com/scriptcenter. Accessed 4 Feb 2023
Shoichet BK (2004) Virtual screening of chemical libraries. Nature 432:862–865
Hosea NA, Jones HM (2013) Predicting pharmacokinetic profles using in silico derived parameters. Mol Pharm 10:1207–1215. https://doi.org/10.1021/mp300482w
Hosea NA, Jones HM (2013) Predicting pharmacokinetic profiles using in silico derived parameters. Mol Pharm 10:1207–1215. https://doi.org/10.1021/mp300482w
Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25. https://doi.org/10.1016/s0169-409x(00)00129-0
Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43(20):3714–3717. https://doi.org/10.1021/jm000942e
Baell JB, Nissink JW (2018) Seven year itch: pan-assay interference compounds (PAINS) in 2017—utility and limitations. ACS Chem Biol 13(1):36–44. https://doi.org/10.1021/acschembio.7b00903
Hospital A, Goñi JR, Orozco M, Gelpí JL (2015) Molecular dynamics simulations: advances and applications. Adv Appl Bioinform Chem 8:37–47. https://doi.org/10.2147/AABC.S70333
Pearlman DA, Charifson PS (2001) Are free energy calculations useful in practice? A comparison with rapid scoring functions for the p38 MAP kinase protein system. J Med Chem 44:3417–3423. https://doi.org/10.1021/jm0100279
Taylor RD, Jewsbury PJ, Essex JW (2002) A review of protein-small molecule docking methods. J Comput Aided Mol Des 16:151–166. https://doi.org/10.1023/a:1020155510718
Wang E, Sun H, Wang J, Wang Z, Liu H, Zhang JZ, Hou T (2019) End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev 119(16):9478–9508. https://doi.org/10.1021/acs.chemrev.9b00055
Wang C, Greene DA, Xiao L, Qi R, Luo R (2018) Recent developments and applications of the MMPBSA method. Front Mol Biosci 4:87. https://doi.org/10.3389/fmolb.2017.00087
Acknowledgements
The authors would like to thank the Bioinformatics Research Center in Isfahan University of Medical Sciences, Isfahan, I.R. Iran for financing and supporting this project (Grant No. 299006 to H.S).
Funding
The study was supported by Isfahan University of Medical Sciences (Grant No. 299006).
Author information
Authors and Affiliations
Contributions
BY and HS designed research. BY, FJE, SB, PACW, and HS compiled and analyzed data. BY, FJE, SB, and HS performed computations. BY, SB, and HS wrote the manuscript. HS supervised the project.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This is a purely computational study and ethics approvals are not applicable.
Consent to participate
Not applicable.
Consent for publication
All co-authors have read and approved the manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yazdani, B., Sirous, H., Enguita, F.J. et al. Discovery of novel direct small-molecule inhibitors targeting HIF-2α using structure-based virtual screening, molecular dynamics simulation, and MM-GBSA calculations. Mol Divers 28, 1203–1224 (2024). https://doi.org/10.1007/s11030-023-10650-6
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1007/s11030-023-10650-6